By Michele Maatouk
Date: Monday 17 Jun 2024
(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty company focusing on providing anti-infective treatments and other critical care therapies, for up to $185m.
Hikma will buy parts of Xellia's US finished dosage form (FDF) business and assets, including...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news